Avidity biosciences joins with patient communities to raise awareness during national muscular dystrophy awareness month as it advances three muscular dystrophy clinical programs

Avidity supports world duchenne awareness day, international myotonic dystrophy awareness day, fshd society walk & roll to cure fshd and global genes week in rare avidity joins with mdf community leaders, patients, caregivers, and legislators in educational briefing to highlight the latest scientific advancements in myotonic dystrophy research and development company advancing clinical development programs for three types of muscular dystrophy – dm1, dmd and fshd – with planned data readouts over the next 12 months san diego , sept. 7, 2023 /prnewswire/ -- avidity biosciences, inc. (nasdaq: rna), a biopharmaceutical company committed to delivering a new class of rna therapeutics called antibody oligonucleotide conjugates (aocs™), today announced that it is joining with patient communities to raise awareness during national muscular dystrophy awareness month, an annual observance that takes place every september to support families across the u.s. who are impacted by neuromuscular diseases.
RNA Ratings Summary
RNA Quant Ranking